Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 19 2024 - 7:30AM
Business Wire
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin”
or the “Company”), a clinical-stage biopharmaceutical
company committed to revolutionizing mental healthcare by
developing new and innovative next-generation psychedelic treatment
options, is pleased to announce that Doug Drysdale, Cybin’s Chief
Executive Officer, will participate in a fireside chat at the H.C.
Wainwright 5th Annual Neuro Perspectives Virtual Conference, taking
place June 27, 2024.
Mr. Drysdale’s fireside chat will be available on demand
beginning on Thursday, June 27, 2024, at 7:00 a.m. ET. To listen to
the event, please click here to access the webcast. The archived
webcast will also be available on the Company’s investor relations
website on the Events & Presentations page.
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission
to create safe and effective psychedelic-based therapeutics to
address the large unmet need for new and innovative treatment
options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported
by a network of world-class partners and internationally recognized
scientists aimed at progressing proprietary drug discovery
platforms, innovative drug delivery systems, and novel formulation
approaches and treatment regimens. The Company is currently
developing CYB003, a proprietary deuterated psilocybin analog for
the treatment of major depressive disorder and CYB004, a
proprietary deuterated DMT molecule for generalized anxiety
disorder and has a research pipeline of investigational
psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is
operational in Canada, the United States, the United Kingdom, the
Netherlands and Ireland. For company updates and to learn more
about Cybin, visit www.cybin.com or follow the team on X, LinkedIn,
YouTube and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240619694356/en/
Investor & Media Contact: Gabriel Fahel Chief Legal
Officer Cybin Inc. 1-866-292-4601 irteam@cybin.com – or –
media@cybin.com